期刊文献+

雌激素拮抗剂ICI-182780对ZDY101调节CHOm_2细胞M_2受体密度的影响

The effect of estrogen antanogist ICI-182780 on the regulatory action of ZDYIOI on M_2 receptor density in CHOm_2 cells
暂未订购
导出
摘要 CHOm2细胞加雌二醇、ZDY101或等体积溶媒DMSO培养后通过3H-NMS结合反应测定M受体密度,并与同时加雌激素受体拮抗剂ICI-182780的细胞作对比。结果显示:雌二醇组M受体密度为(123.7±23.9)fmol·mg-1,加ICI-182780后为(84.8±19.8)fmol·mg-1;相应的DMSO对照组为(89.6±22.9)fmol·mg-1,加ICI后为(66.9±22.5)fmol·mg-1;雌二醇组加ICI-182780后M受体密度降低的幅度远大于DMSO对照组。ZDY101组M受体密度为(147.3±36.9)fmol·mg-1,加ICI-182780后为(120.8±40.4)fmol·mg-1;相应的DMSO对照组为(95.9±24.0)fmol·mg-1,加ICI-182780后为(77.0±22.3)fmol·mg-1。表明雌激素和ZDY101都具有的提高M受体密度的功效,雌激素的药效可被ICI抑制,而ZDY101的药效不被ICI抑制,说明ZDY101有不同于雌激素的作用机制。 After the treatment of estradiol, ZDYIOI or DMSO (solvent) to cultured CHOm2 cells for a certain peirod, M-receptor density was determined by 3H-NMS binding assay. Parallel observations were carried out with or without the addition of ICI-182780. The Results show that the density of M receptor in cells treated with estradiol or DMSO control were 123.7±23.9 and 89.6±22.9fmol/mg protein, and these values dropped down to 84.8±19.8 and 66.9±22.5fmol/mg with the presence of ICI-182780. The density of M receptor in cells treated by ZDYIOI or DMSO control were 147.3±36.9 and 95.9±24.0fmol/mg, and dropped to 120.8±40.4 and 77.0±22.3fmol/mg protein with the presence of ICI-182780. ICI-182780 caused a much greater decrease of M receptor density in estradiol treated cells than DMSO control cells indicating that estradioi increased the M receptors through action on estradiol receptor. The magnitude of decrease of M receptor density induced by ICI-182780 in ZDYIOI treated group was similar to that in DMSO controls, indicating that the increase of M receptor density induced by ZDY101 could not be inhibited by ICI-182780 and hence had a mechanism different from estradiol.
出处 《核技术》 CAS CSCD 北大核心 2003年第11期845-848,共4页 Nuclear Techniques
基金 国家自然科学基金(30070926)资助
关键词 M受体 阿尔采默病 ZDY101 知母 雌二醇 ICI-182780 M-receptor, AD (Alzheimer's disease), ZDY101, Zhimu, Estradiol, ICI-182780
  • 相关文献

参考文献12

  • 1Seshadri S, Wolf P A, Beiser A, et al. Neurology, 1997,49:1498-1504.
  • 2YI Ningyu, HU Yaer, XIA Zongqin, In: ZHOU Jinhuang,WANG Jianhua, ed. Progress in pharmacology and clinics of Chinese materia medica, Beijing: Publisher of Military Medicine Sciences 1996, 4:180-192.
  • 3Mcewen B S. J Clin Endocrinol Metab, 1999, 84:1790-1797.
  • 4Gibbs R B, Ann N Y Acad Sci, 1994, 743:165-196.
  • 5Steffens D C, Norton M C, Plassman B L. et al. J Am Geriatr Soc, 1999, 47:1171-1175.
  • 6Epperson C N, Wisher K L, Yamamoto B. Psychosom Med, 1999, 61:676-697.
  • 7Wakeling A E, Dukes M, Bowler J. Cancer Research 1991, 51:3867-3873.
  • 8Sill Ju, HU Yaer, YI Ningyu, et al. Acta Universitatis Medicinalis Secondae Shanghai, 2000, 20:503-505.
  • 9Parisot J P, Hu X F, Sutherland R L, et al. International J Cancer, 1995, 62:480-r484.
  • 10Dudley M W, Sheeler C Q, Wang H, et al. Proc Nail Acad Sci USA 2000, 97:3696-3701.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部